Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Eikon Therapeutics CEO Roger M. Perlmutter will participate in a Key Opinion Leader event hosted by Cantor Fitzgerald on August 20, 2026. The event features Dr. Timothy A.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.